Home Cart Sign in  
Chemical Structure| 140898-91-5 Chemical Structure| 140898-91-5

Structure of Hexaminolevulinate HCl
CAS No.: 140898-91-5

Chemical Structure| 140898-91-5

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Hexaminolevulinate HCl is a fluorescent agent which has been approved for cystoscopic detection of papillary bladder cancer.

Synonyms: Hexyl 5-aminolevulinate hydrochloride; P-1206; Hexyl 5- aminolevulinate

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Hexaminolevulinate HCl

CAS No. :140898-91-5
Formula : C11H22ClNO3
M.W : 251.75
SMILES Code : Cl.CCCCCCOC(=O)CCC(=O)CN
Synonyms :
Hexyl 5-aminolevulinate hydrochloride; P-1206; Hexyl 5- aminolevulinate
MDL No. :MFCD03695491
InChI Key :LZYXPFZBAZTOCH-UHFFFAOYSA-N
Pubchem ID :6433082

Safety of Hexaminolevulinate HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H317-H319-H335
Precautionary Statements:P261-P280-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02800473 Bladder Cancer Not Applicable Completed - France ... More >> Institut de Cancerologie de Lorraine Vandoeuvre-les-Nancy, France, 54519 Less <<
NCT02857634 - Completed - France ... More >> Groupement des Hôpitaux de l'Institut Catholique de Lille Lomme, Nord, France, 59462 Less <<
NCT03058705 Bladder Cancer Not Applicable Completed - United States, New York ... More >> University of Rochester Medical Center Rochester, New York, United States, 14642 Less <<
NCT02149342 Actinic Keratoses Phase 1 Phase 2 Completed - Finland ... More >> Päijät-Häme Central Hospital Lahti, Finland, 15850 Less <<
NCT02149342 - Completed - -
NCT03272659 Colorectal Cancer ... More >> Photodynamic Diagnosis Less << Phase 2 Withdrawn(Long process and due... More >> to strict deadline, project was stopped.) Less << April 1, 2019 -
NCT00496171 - Terminated - Norway ... More >> Riks-Radium University Hospital Oslo, Norway Less <<
NCT02560584 Bladder Cancer Phase 3 Completed - United States, California ... More >> USC Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637 United States, Iowa University of Iowa Iowa City, Iowa, United States, 52242 United States, Maryland Johns Hopkins University Baltimore, Maryland, United States, 21205 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, New York Montefiore Medical Center Bronx, New York, United States, 10461 NYU Langone Urology Associates New York, New York, United States, 10016 Columbia University Medical Center New York, New York, United States, 10032 United States, North Carolina University of North Carolina, Department of Urology Chapel Hill, North Carolina, United States, 27599 United States, Ohio Ohio State University The James Cancer Hospital Columbus, Ohio, United States, 43210 United States, Oklahoma University of Oklahoma-Stephenson Cancer Center Oklahoma City, Oklahoma, United States, 73104 United States, Pennsylvania Thomas Jefferson University Philadelphia, Pennsylvania, United States, 10197 United States, Tennessee Vanderbilt University Medical Center Nashville, Tennessee, United States, 37232 United States, Texas UT Southwestern Medical Center Dallas, Texas, United States, 75390 MD Anderson Cancer Center Houston, Texas, United States, 77030 Michael E. DeBakey VA Medical Center Houston, Texas, United States, 77030 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53792 Less <<
NCT02660190 Bladder Cancer ... More >> Recurrence PDD Less << Phase 3 Active, not recruiting October 2018 Denmark ... More >> Herlev Hospital Herlev, Denmark Hospitalsenheden Vest Holstebro, Denmark Less <<
NCT01750970 Bladder Tumor Not Applicable Completed - France ... More >> Hôpital FOCH Suresnes, France, 92150 Less <<
NCT02560584 - Completed - -
NCT00369018 Cervical Dysplasia Phase 1 Phase 2 Completed - Germany ... More >> Medizinische Hochschule Hannover, Department of Obstetrics and Gynecology Hannover, Germany, 30625 Norway Ullevål University Hospital, Department of Obstetrics and Gynecology Oslo, Norway, 0407 Less <<
NCT01256424 - Completed - -
NCT01256424 Cervical Intraepithelial Neopl... More >>asia Less << Phase 2 Completed - Germany ... More >> University Hospital Hannover Hannover, Germany Norway Haukeland University Hospital Bergen, Norway, 5021 Less <<
NCT01282515 Genital Erosive Lichen Planus Phase 2 Phase 3 Unknown - Norway ... More >> Rikshospitalet, OsloUniversity hospital Oslo, Norway, 0027 Less <<
NCT00708942 Cervical Intraepithelial Neopl... More >>asia Less << Phase 2 Terminated(Slow recruitment, s... More >>tudy stopped with only 13 of 70 patients included in second part of the study) Less << - France ... More >> Department of Obstetrics and Gyneacology, Lille University Hospital Lille, France Germany Department of Obstetrics and Gynecology Hannover, Germany Norway Fritzøe klinikk Larvik, Norway Department of Obstetrics and Gynaecology, Ullevål University Hospital Oslo, Norway Medicus Trondheim, Norway Less <<
NCT02660645 - Recruiting December 2020 United States, California ... More >> USC/Norris Comprehensive Cancer Center Recruiting Los Angeles, California, United States, 90033 Contact: Ileana Aldana    323-865-0702    ileana.aldana@med.usc.edu    Principal Investigator: Sia Daneshmand, MD          Sub-Investigator: Anne Schuckman, MD          Sub-Investigator: Mihir Desai, MD          Sub-Investigator: Hooman Djaladat, MD          Sub-Investigator: Gerhard Fuchs, MD          Sub-Investigator: Virinder Bhardwaj, MD          VA Palo Alto Health Care System Recruiting Palo Alto, California, United States, 94304 Contact: Dorothy Trivedi       dtrivedi@stanford.edu    Principal Investigator: Joseph Liao, MD          Sub-Investigator: James Crotty, MD          Sub-Investigator: John Leppert, MD          Sub-Investigator: John Lavelle, MD          University of California, San Francisco Recruiting San Francisco, California, United States, 94143 Contact: Sima Porten, MD, MPH    415-885-3695    Sima.Porten@ucsf.edu    Principal Investigator: Sima Porten, MD, MPH          United States, Kansas University of Kansas Medical Center Recruiting Kansas City, Kansas, United States, 66160 Contact: Katie Glavin    913-588-8721    kglavin@kumc.edu    Principal Investigator: John Taylor, MD, MS          Sub-Investigator: Jeffrey Holzbeierlein, MD, FACS          Sub-Investigator: Eugene Lee, MD, FACS          Sub-Investigator: Hadley Wyre, MD          Sub-Investigator: Moben Mirza, MD          United States, Maryland Johns Hopkins Medicine Recruiting Baltimore, Maryland, United States, 21224 Contact: Morgan De Carli       Mdecarl2@jhmi.edu    Principal Investigator: Trinity Bivalacqua, MD, PhD          Sub-Investigator: Phillip Pierorazio, MD          United States, Minnesota University of Minnesota Recruiting Minneapolis, Minnesota, United States, 55455 Contact: Therese Perrier    612-625-3319    perri084@umn.edu    Principal Investigator: Badrinath Konety, MD          Sub-Investigator: Weight Chris, MD          Sub-Investigator: Laureen Hemsley, MD          United States, New York Stony Brook Urology Recruiting Stony Brook, New York, United States, 11794 Contact: Kim Lyktey       Kim.Lyktey@stonybrookmedicine.edu    Principal Investigator: John Fitzgerald, MD          Sub-Investigator: Massimiliano Spaliviero, MD          Sub-Investigator: Wayne Waltzer, MD          United States, Ohio Cincinnati VA Medical Center Not yet recruiting Cincinnati, Ohio, United States, 45220 Contact: Krishnanath Gaitonde, MD          Principal Investigator: Krishnanath Gaitonde, MD          Ohio State University Wexner Medical Center Recruiting Columbus, Ohio, United States, 43210 Contact: Kamal Pohar, MD       kamal.pohar@osumc.edu    Principal Investigator: Kamal Pohar, MD          Sub-Investigator: Megan Merrill, DO          Sub-Investigator: Ahmad Shabsigh, MD          Sub-Investigator: David Sharp, MD          United States, South Carolina Carolina Urology Partners Recruiting West Columbia, South Carolina, United States, 29169 Contact: Nicol Brandon    704-414-2870 ext 2809    Nicol.brandon@carolinaurologypartners.com    Principal Investigator: T. Brian Willard, MD          Sub-Investigator: David Lamb, MD          Sub-Investigator: Scott Sweazy, MD          Sub-Investigator: Keith Birghtbill, MD          Sub-Investigator: Michael Stotzer, MD          United States, Texas UT Southwestern Not yet recruiting Dallas, Texas, United States, 75390 Contact: Yair Lotan, MD    214-645-8787       Principal Investigator: Yair Lotan, MD          Sub-Investigator: Aditya Bagrodia, MD          Sub-Investigator: Vitaly Margulis, MD          Sub-Investigator: Ganesh Raj, MD, PhD          Michael E. DeBakey VA Medical Center Recruiting Houston, Texas, United States, 77030 Contact: Ashley Jones, BS, CCRP    713-791-1414 ext 26694    Ashley.Jones2@bcm.edu    Principal Investigator: Jennifer Taylor, MD, MPH          Sub-Investigator: Jeffrey Jones, MD          Sub-Investigator: Sidney Worsham, MD          United States, West Virginia Charleston Area Medical Center Recruiting Charleston, West Virginia, United States, 25301 Contact: James Tierney, DO    304-388-9944       Principal Investigator: James Tierney, DO          Sub-Investigator: Samuel Deem, DO Less <<
NCT00285701 Colorectal Cancer Phase 1 Phase 2 Completed - Germany ... More >> Dept of Medicine, Munic-Hospital Pasing Munic, Bayern, Germany Less <<
NCT00708942 - Terminated(Slow recruitment, s... More >>tudy stopped with only 13 of 70 patients included in second part of the study) Less << - -
NCT00052637 Bladder Cancer Phase 3 Completed - United States, California ... More >> Jonsson Comprehensive Cancer Center, UCLA Los Angeles, California, United States, 90095 Less <<
NCT02367547 Neoplasms, Basal Cell ... More >> Carcinoma, Basal Cell Photochemotherapy Photosensitizing Agents Less << Phase 1 Phase 2 Recruiting December 2022 Finland ... More >> Joint Authority for Päijät-Häme Social and Health Care Recruiting Lahti, Finland, 15850 Less <<
NCT01050309 Pharmacokinetics Phase 1 Completed - Netherlands ... More >> Pra-Eds-Nl Zuidlaren, Netherlands, 9471 Less <<
NCT01166230 - Completed - -
NCT01166230 - Completed - -
NCT01344902 Colon Cancer Phase 1 Phase 2 Terminated(The study was stopp... More >>ed due to inadequate efficacy after 13 patients were evaluated.) Less << - Germany ... More >> Klinikum München Pasing Munich, Germany, 81241 Less <<
NCT00412971 Bladder Cancer Phase 3 Completed - Denmark ... More >> Frederiksberg Hospital Frederiksberg, Denmark, 2000 Odense University Hospital Odense, Denmark Less <<
NCT02012036 - Completed - Germany ... More >> Caritas-Krankenhaus St. Josef, Klinik fuer Urologie Regensburg, Germany, 93059 Klinikverbund Südwest Sindelfingen, Germany, 71065 Less <<
NCT00785694 Bladder Cancer Phase 4 Withdrawn(Rejected ethics appr... More >>oval in UK and Holland) Less << - France ... More >> GE Healthcare Medical Diagnostics Velizy Cedex, Morane Saulnier, France, 78457 Less <<
NCT00412971 - Completed - -
NCT01551407 Bladder Cancer Phase 2 Terminated(slow inclusion rate... More >>) Less << - Germany ... More >> LMU Munich Munich, Germany, D-81377 Less <<
NCT00233402 Bladder Cancer Phase 3 Completed - -
NCT00233402 - Completed - -
NCT01303991 Intermediate or High-risk Blad... More >>der Cancer Less << Phase 1 Completed - -
NCT00634621 - Completed - -
NCT00634621 - Completed - Spain ... More >> GE Healthcare Madrid, Spain, 28108 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.97mL

0.79mL

0.40mL

19.86mL

3.97mL

1.99mL

39.72mL

7.94mL

3.97mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

[1]Rose JB, Armstrong S, et al. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden. BJU Int. 2016 Jun;117(6B):E102-13.

[2]Garfield SS, Gavaghan MB, et al. The cost-effectiveness of blue light cystoscopy in bladder cancer detection: United States projections based on clinical data showing 4.5 years of follow up after a single hexaminolevulinate hydrochloride instillation. Can J Urol. 2013 Apr;20(2):6682-9.

[3]Rose JB, Armstrong S, Hermann GG, Kjellberg J, Malmström PU. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden. BJU Int. 2016 Jun;117(6B):E102-13

[4]Di Stasi SM, De Carlo F, Pagliarulo V, Masedu F, Verri C, Celestino F, Riedl C. Hexaminolevulinate hydrochloride in the detection of nonmuscle invasive cancer of the bladder. Ther Adv Urol. 2015 Dec;7(6):339-50

[5]Chan KM, Gleadle J, Vasilev K, MacGregor M. Probing Hexaminolevulinate Mediated PpIX Fluorescence in Cancer Cell Suspensions in the Presence of Chemical Adjuvants. Int J Mol Sci. 2020 Apr 22;21(8):2963

[6]Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S. Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018. Nat Rev Urol. 2019 Jun;16(6):377-386

 

Historical Records

Categories